Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125632152 | 12563215 | 2 | F | 20160711 | 20160715 | 20160718 | EXP | KR-SA-2016SA127280 | AVENTIS | CHOI JE, CHOE AR, YOON SE, NAM EM, PARK H, LEE KE. GERM CELL TUMOR TARGETING CHEMOTHERAPY IN GASTRIC ADENOCARCINOMA WITH AN ENDODERMAL SINUS TUMOR COMPONENT: A CASE REPORT. CHEMOTHERAPY 2017;62:54-7. DOI: 10.1159/000447117. ACCESSED: 2016 JUN 29. | 77.00 | YR | E | M | Y | 0.00000 | 20160718 | OT | KR | KR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125632152 | 12563215 | 1 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 2 | SS | BLEOMYCIN | BLEOMYCIN SULFATE | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 3 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 4 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 5 | SS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 6 | SS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 7 | SS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 8 | SS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 9 | PS | OXALIPLATIN. | OXALIPLATIN | 1 | Unknown | UNK | 21759 | ||||||||||
| 125632152 | 12563215 | 10 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Unknown | UNK | 21759 | ||||||||||
| 125632152 | 12563215 | 11 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Unknown | UNK | 21759 | ||||||||||
| 125632152 | 12563215 | 12 | SS | OXALIPLATIN. | OXALIPLATIN | 1 | Unknown | UNK | 21759 | ||||||||||
| 125632152 | 12563215 | 13 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | UNK | 0 | ||||||||||
| 125632152 | 12563215 | 14 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125632152 | 12563215 | 1 | Adenocarcinoma gastric |
| 125632152 | 12563215 | 2 | Metastases to liver |
| 125632152 | 12563215 | 3 | Adenocarcinoma gastric |
| 125632152 | 12563215 | 4 | Metastases to liver |
| 125632152 | 12563215 | 5 | Adenocarcinoma gastric |
| 125632152 | 12563215 | 6 | Metastases to liver |
| 125632152 | 12563215 | 7 | Adenocarcinoma gastric |
| 125632152 | 12563215 | 8 | Metastases to liver |
| 125632152 | 12563215 | 9 | Adenocarcinoma gastric |
| 125632152 | 12563215 | 10 | Metastases to liver |
| 125632152 | 12563215 | 11 | Adenocarcinoma gastric |
| 125632152 | 12563215 | 12 | Metastases to liver |
| 125632152 | 12563215 | 13 | Adenocarcinoma gastric |
| 125632152 | 12563215 | 14 | Metastases to liver |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125632152 | 12563215 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125632152 | 12563215 | Pneumonia | |
| 125632152 | 12563215 | Product use issue | |
| 125632152 | 12563215 | Pulmonary mass | |
| 125632152 | 12563215 | Therapeutic response decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |